TaiMed Biologics Inc. is a commercial-stage biologics company focused on developing CD4-targeted antibody therapies for long-acting HIV treatment and broader immune-directed applications. The company’s portfolio includes Trogarzo, the first FDA-approved monoclonal antibody for HIV treatment, and its lead clinical program, TMB-365/380, a dual-antibody regimen in Phase 2b for HIV maintenance therapy. TaiMed also operates a contract development and manufacturing organization (CDMO) division that provides integrated services including process development, analytical development, formulation, cGMP manufacturing, and regulatory support to external partners. The company collaborates with research institutions such as the Aaron Diamond AIDS Research Center, The Rockefeller University, and the National Institutes of Health.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage taimedbiologics.com
Sector Healthcare IR page taimedbiologics.com
Tags
hiv treatment, monoclonal antibodies, cdmo services, long-acting therapy, antibody-drug conjugates, biologics manufacturing, clinical development, Trogarzo, TMB-365/380, CD4-ADC
Press page —

Metrics

Valuation  
Market cap NT$ 15.402B
Market cap (USD) $ 467.491M
P/E -94.83
PEG —
P/BV 4.23
P/S 23.70
P/OCF -40.58
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE -4.3%
ROI -4.3%
ROIC -3.8%
Profit margin -27.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -43.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Revenue 611.35M 610.162M 491.777M 563.008M 413.442M 722.485M 704.504M 241.041M 8.436M 2.076M — — — 0 135K 0
Net profit -167.776M -201.832M -194.81M -269.289M -470.933M -183.304M -578.654M -321.71M -524.554M -281.962M -471.68M -281.735M -251.677M -207.298M -204.52M -238.207M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010
Share price 61.2 — — — — — — — — — — — — — — —
P/S 27.35 — — — — — — — — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

公告本公司法人董事改派法人代表人 Bull 0 Bear 0 Management

Prompts

TaiMed Biologics Inc. (ticker 4147.TWO), listed in Taiwan.

ETFs Holding TaiMed Biologics Inc.

ETF Weight in ETF Shares Market value As of
AVEE 0.03% 21,000 $ 39.967K Nov 16, 2026
AVEM 0.00% 27,000 $ 51.386K Nov 16, 2026